



SEMI ANNUAL REPORT
(*FINANCIAL STATEMENTS*)

AS PER JUNE 30, 2021

Aescap Life Sciences**Contents**

General Information	2
Overview (Key figures) Aescap Life Sciences	3
Profile & Structure	6
Financial Statements	13
Balance Sheet as per June 30, 2021	14
Profit & Loss Account for the period January 1, 2021 – June 30, 2021.....	15
Statement of Cash Flows for the period January 1, 2021 – June 30, 2021	16
Notes	17
Notes to the Balance Sheet.....	20
Notes to the Profit & Loss Account.....	23
Other Information	26

Aescap Life Sciences

General Information

Business Address of the Fund

Aescap Life Sciences
Gustav Mahlerplein 3, 26th floor, Financial Offices
1082 MS Amsterdam
The Netherlands
www.aescap.com
E-mail : info@priviumfund.com

Fund Manager

Privium Fund Management B.V.
Gustav Mahlerplein 3, 26th floor, Financial Offices
1082 MS Amsterdam
The Netherlands
E-mail : info@priviumfund.com

Legal Owner

Stichting Aescap Life Sciences
Hoogoorddreef 15
1101 BA AMSTERDAM
The Netherlands
www.iqeq.com

Administrator

IQ EQ Financial Services B.V.
Hoogoorddreef 15
1101 BA AMSTERDAM
The Netherlands
www.iqeq.com

Independent auditor

Mazars Accountants N.V.
Delflandlaan 1
1062 EA Amsterdam
The Netherlands

Custodian

Saxo Bank Nederland
Barbara Strozziilaan 310
1083 HN AMSTERDAM
The Netherlands

Depositary

Darwin Depositary Services B.V.
Barbara Strozziilaan 101
1083 HN Amsterdam
E-mail : info@darwindepository.com

Legal Counsel

Warendorf
Koningslaan 42
1075 AE Amsterdam
The Netherlands

Regulatory Counsel

Finnius
Jollemanhof 20A
1019 GW Amsterdam
The Netherlands

Aescap Life Sciences**Overview (Key figures) Aescap Life Sciences**

	30-06-21	31-12-20	31-12-19	31-12-18	31-12-17
Number of Outstanding Units					
Aescap Life Sciences Fund management	11,342.5267	11,277.4464	9,685.2839	9,137.7023	7,085.3465
Aescap Life Sciences Investors	66,933.0375	55,383.1535	56,584.4102	36,133.6551	19,431.2623
Aescap Life Sciences Investors 011117	-	-	-	-	84.0062
Aescap Life Sciences Investors 011217	-	-	-	-	3,319.4737
Aescap Life Sciences Investors 011118	-	-	-	658.0455	-
Aescap Life Sciences Investors 011218	-	-	-	2,001.6451	-
Aescap Life Sciences Investors 010320	-	1,326.3169	-	-	-
Aescap Life Sciences Investors 010420	-	896.4172	-	-	-
Aescap Life Sciences Investors 010520	-	442.2221	-	-	-
Aescap Life Sciences Investors 010620	-	778.9980	-	-	-
Aescap Life Sciences Investors 010720	-	415.1420	-	-	-
Aescap Life Sciences Investors 010820	-	866.6663	-	-	-
Aescap Life Sciences Investors 010920	-	1,736.1909	-	-	-
Aescap Life Sciences Investors 01020	-	428.6512	-	-	-
Aescap Life Sciences Investors 011120	-	127.4024	-	-	-
Aescap Life Sciences Investors 011220	-	584.6191	-	-	-
Aescap Life Sciences Investors 150320	-	1,284.8219	-	-	-
Aescap Life Sciences Investors 150420	-	2,148.8197	-	-	-
Aescap Life Sciences Investors 150520	-	119.9755	-	-	-
Aescap Life Sciences Investors 150620	-	518.2202	-	-	-
Aescap Life Sciences Investors 150720	-	1,987.2639	-	-	-
Aescap Life Sciences Investors 150820	-	197.8006	-	-	-
Aescap Life Sciences Investors 150920	-	311.2360	-	-	-
Aescap Life Sciences Investors 151020	-	488.6568	-	-	-
Aescap Life Sciences Investors 151120	-	163.3502	-	-	-
Aescap Life Sciences Investors 151220	-	42.6949	-	-	-
Aescap Life Sciences Investors 10M+	6,025.8724	-	-	6,876.0000	-
Aescap Life Sciences Investors 20M+	-	8,972.1209	10,760.8981	-	-
Aescap Life Sciences Investors 20M+ 150920	-	2,561.0991	-	-	-
Aescap Life Sciences Investors 1321	11.9348	-	-	-	-
Aescap Life Sciences Investors 1421	1,406.8225	-	-	-	-
Aescap Life Sciences Investors 1521	457.8220	-	-	-	-
Aescap Life Sciences Investors 15321	1,188.2366	-	-	-	-
Aescap Life Sciences Investors 15421	369.5791	-	-	-	-
Aescap Life Sciences Investors 15521	206.5161	-	-	-	-
Aescap Life Sciences Investors 15621	434.6017	-	-	-	-
Aescap Life Sciences Investors 1621	9.9129	-	-	-	-

Aescap Life Sciences**Overview (Key figures) Aescap Life Sciences – Continued**

	30-06-21	31-12-20	31-12-19	31-12-18	31-12-17
Net Asset Value per Unit (€)					
Aescap Life Sciences Fund management	2,863.5633	2,859.8896	2,871.2641	2,104.7655	1,283.4951
Aescap Life Sciences Investors	2,160.1228	2,173.9341	2,242.1433	1,725.0062	1,174.4191
Aescap Life Sciences Investors 011117	-	-	-	-	1,174.4190
Aescap Life Sciences Investors 011217	-	-	-	-	1174.4191
Aescap Life Sciences Investors 011118	-	-	-	1,702.5930	-
Aescap Life Sciences Investors 011218	-	-	-	1,725.0062	-
Aescap Life Sciences Investors 010320	-	2,130.0782	-	-	-
Aescap Life Sciences Investors 010420	-	2,083.3346	-	-	-
Aescap Life Sciences Investors 010520	-	2,135.7602	-	-	-
Aescap Life Sciences Investors 010620	-	2,173.9342	-	-	-
Aescap Life Sciences Investors 010720	-	2,172.6857	-	-	-
Aescap Life Sciences Investors 010820	-	2,133.4324	-	-	-
Aescap Life Sciences Investors 010920	-	2,129.6367	-	-	-
Aescap Life Sciences Investors 01020	-	2,123.5867	-	-	-
Aescap Life Sciences Investors 011120	-	2,130.7462	-	-	-
Aescap Life Sciences Investors 011220	-	2,166.2682	-	-	-
Aescap Life Sciences Investors 150320	-	2,031.9849	-	-	-
Aescap Life Sciences Investors 150420	-	2,116.6085	-	-	-
Aescap Life Sciences Investors 150520	-	2,149.9855	-	-	-
Aescap Life Sciences Investors 150620	-	2,163.6563	-	-	-
Aescap Life Sciences Investors 150720	-	2,157.1159	-	-	-
Aescap Life Sciences Investors 150820	-	2,136.6274	-	-	-
Aescap Life Sciences Investors 150920	-	2,121.5017	-	-	-
Aescap Life Sciences Investors 151020	-	2,152.6574	-	-	-
Aescap Life Sciences Investors 151120	-	2,159.4978	-	-	-
Aescap Life Sciences Investors 151220	-	2,160.7431	-	-	-
Aescap Life Sciences Investors 10M+	2,200.5532	-	-	1,733.2246	-
Aescap Life Sciences Investors 20M+	-	2,212.7206	2,269.9959	-	-
Aescap Life Sciences Investors 20M+ 150920	-	2,169.6584	-	-	-
Aescap Life Sciences Investors 1321	2,147.9128	-	-	-	-
Aescap Life Sciences Investors 1421	2,142.0653	-	-	-	-
Aescap Life Sciences Investors 1521	2,138.6706	-	-	-	-
Aescap Life Sciences Investors 15321	2,154.6850	-	-	-	-
Aescap Life Sciences Investors 15421	2,134.4061	-	-	-	-
Aescap Life Sciences Investors 15521	2,108.0309	-	-	-	-
Aescap Life Sciences Investors 15621	2,160.1228	-	-	-	-
Aescap Life Sciences Investors 1621	2,124.5872	-	-	-	-
Total Net Asset Value (x € 1,000)	199,086,451	209,693,074	179,106,560	98,055,693	35,911,566

The abovementioned Investor Unit Classes have equal conditions, the only differences being applied are the fees.

Aescap Life Sciences**Overview (Key figures) Aescap Life Sciences – Continued**

	30-06-21	31-12-20	31-12-19	31-12-18	31/12/2017 (2)
Return on Investment per Unit (%)					
Aescap Life Sciences Fund management	0.13%	(0.40%)	36.42%	63.99%	28.35%
Aescap Life Sciences Investors	(0.64%)	(3.04%)	29.98%	46.88%	17.44%
Aescap Life Sciences Investors 10M+	(0.55%)	-	-	-	-
Aescap Life Sciences Investors 20M+	-	(2.52%)	11.60% (3)	-	-
Ongoing Cost Figure (OCF) – previously Total Expense Ratio (TER) (1)					
OCF (Performance Fee excluded (%))	1.62%	1.63%	1.64%	1.61%	3.09%
OCF (Performance Fee included (%))	1.66%	3.02%	5.70%	13.21%	9.54%

(1) the OCF figures are valid for the Aescap Investors Unit Class (Lead Series), whereas the fund management shares do not have management fee charged. OCF figures are on an annual basis.

(2) figures are valid for the period equalizing the extended bookyear March 2016 – December 2017 (21 month period).

(3) figures are valid for the period mid July 2019 – December 2019.

The 2017 ongoing cost figure equals on an annual basis 1.77% and has been calculated by dividing the reporting period figure by 21 and having multiplied this figure by 12.

Aescap Life Sciences

Profile & Structure

Start of the Fund

Aescap Life Sciences ("the Fund") started activities as per March 28, 2016. The Fund has been established for an indefinite period of time.

Legal Form

The Fund is a fund for joint account (in Dutch: een fonds voor gemene rekening). It does not have a legal personality. It is formed by and comprises a contractual arrangement governed by the terms of this Prospectus between the Fund Manager, the Legal Owner and each Unit Holder. Under this arrangement the Fund Manager is mandated to invest the contributions of the Unit Holders of the Fund for their collective risk and account in securities, which are held by the Legal Owner on behalf of the Unit Holders, in accordance with the Prospectus for the purpose of enabling the Unit Holders to share in the revenue from the investments in securities. The Unit Holders are proportionally matched with the number of Units owned, and they are jointly entitled to the Fund Assets. The contractual agreement between the Fund Manager, the Legal Owner and each of the Unit Holders does not constitute a partnership or limited partnership and does not create any other agreement between the Unit Holders. The obligation of a Unit Holder to pay the subscription price for a Unit is only an obligation towards the Fund represented by the Fund Manager and the Legal Owner. The Units only constitute rights and obligations of the Unit Holders with respect to the Fund Manager and the Legal Owner and not to other Unit Holders.

Limited Transferability

The Fund has a private character, i.e. Units may only be transferred to the Fund upon a redemption. However, Units may be transferred to persons that are next of kin or direct in law of a Unit Holder. Units may not be pledged or otherwise encumbered.

Open End

Except in certain exceptional circumstances, the Fund is obliged to issue or to redeem Units on a Transaction Day at their Net Asset Value, minus the subscription or redemption fee.

Not listed

The Fund is not listed on any stock exchange.

Net Asset Value

The Net Asset Value is calculated at least twice a month by the Administrator, as is described in Section 13 of this Prospectus ("Determination of Net Asset Value").

Minimum subscription amount

The minimum amount for participation is € 500,000 although the Fund Manager at its discretion can make an exception and lower the minimum to € 101,000 (including the 1% subscription fee). For the clients of wealth managers or private banks who have an executed discretionary portfolio management agreement or investment advisory services agreement with the wealth manager, family office or private bank, subscription amounts below EUR 101,000 are accepted as the investment decision to invest in the Aescap Life Sciences is taken by or advised by the wealth manager, family office or private bank. Additionally, for family members of existing Unit Holders (being defined as first and second degree relatives), subscription amounts below EUR 101,000 can be accepted as well. Here the subscription will be linked to the size of the current investment of the existing Unit Holder. At the time of inception of the Fund Units with a Net Asset Value of € 1,000 have been issued as part of the Initial Series.

Request for issue or redemption

Requests for the issue or redemption of Units may be made to the Administrator by means of the forms provided for this purpose on the Website. The Administrator will inform the Fund Manager. The Fund Manager is not obliged to honor a request for an issue or redemption of Units. (See Section 14, "Subscription", and Section 15, "Redemption".)

Tax Position of Fund

Due to the limited transferability of the Units of the Fund, the Fund qualifies as a tax transparent fund for joint account for Dutch income tax purposes. Consequently, the Fund is not subject to Dutch (corporate) income tax.

Distribution policy

The dividends and interest received by the Fund, as well as possible capital gains, will not be distributed but will be re-invested, unless distribution would be deemed appropriate by the Fund Manager in connection with the regulatory status of the Fund Manager. Any distribution will take place on a pro rata basis.

Regulatory considerations

License

The Fund Manager is in possession of an AFM license as referred to in article 2:65(a) FSA, and as a consequence (and subject to compliance with the other requirements applicable pursuant to the FSA) may offer the Fund to professional and non-professional investors within the Netherlands.

The AFM license of the Fund Manager has been issued prior to the implementation of the AIFM Directive in the Netherlands and was automatically converted into an AIFM Directive license by the AFM on 22 July 2014, in accordance with the Netherlands AIFM Directive implementation schedule.

Supervision by AFM and DNB

The Fund Manager operates under the supervision of the AFM and DNB as foreseen in the applicable provisions of the FSA. For the sake of an adequate functioning of the financial markets and the position of investors, investment funds have to comply with demands with regard to professionalism and reliability of its managers, financial safeguards, (operational) management and the providing of information to Unit Holders, the public and the supervisors.

For "regulatory changes" we refer to page 50, section 21 of the Prospectus.

Aescap Life Sciences

Investment Proposition

The Market Opportunity

Aescap Life Sciences ('the Fund') invests in the shares of publicly listed biotech / life sciences companies. It invests in highly innovative companies that develop and market new medicines and to a lesser extent diagnostics and/or medical devices.

The life sciences market is a large and fast-growing market where breakthrough innovations can be exploited in a global and profitable manner.

The substantial growth of the life sciences market is driven by:

- a) A longer life expectancy (especially in the emerging markets) as well as an ageing population which are driving demand for improved and cost-effective medicine, diagnostics and medical devices;
- b) A high unmet medical need for diseases such as Alzheimer, Arthritis, Diabetes, MS, Obesity, Oncology, Parkinson and many other such as infectious diseases;
- c) The maturation of new technologies such as RNA, cell, and gene therapy.

The rapidly growing healthcare costs, almost everywhere in the world, are increasing the demand for biotech / life sciences innovations. A good example of such an approach is the concept of precision medicine. The concept of precision medicine is based on the fact that people respond differently to the same treatment. Based on gene profiling and biomarker data a patient can be given the right treatment from the start, instead of following a trial and error approach as still often is the case in the treatment of cancer. The development of precision medicine has only just started.

The sector the Fund is active in is known for its attractive premiums in case of takeovers. The large cash buffers of the bigger pharma / biotech companies create the potential for many future acquisitions of smaller (listed) biotech companies.

The number of publicly listed biotech / life sciences companies the Fund can select from is over 750 in the EU and the US together.

Investment Policy

The Fund aims to gain value by investing in publicly traded shares of biopharmaceutical companies and potentially also diagnostics and/or medical device companies. The Fund may also invest in warrants of such companies. Often these warrants are received as part of an equity issue by a company. It will typically invest in companies with the potential to (more than) double their share price over a period of maximum 4-5 years. Given the particular innovation power in biotech in Western Europe and North America most investments will be made in these geographical areas.

The Fund has a focused portfolio, investing in approximately 20 companies. Within this focus it will ensure that the portfolio is diversified over different diseases, development phases and geographical areas.

Investment Objective

The Fund's objective is to make an average minimum annual net return (after deduction of costs) of 20%+ over the mid-term (4-5 years).

Investment Discipline and Criteria

The Fund aims to select those publicly listed biotech / life sciences companies which are undervalued based on their growth potential. The value creation in which it aims to invest is typically based on:

- a significant potential growth in revenues/profit;
- the achievement of clinical study milestones; and/or
- the closing of a partnership or similar deal with a larger biotech / life sciences company in the field, one that most likely already has a sales force active in the disease area the licensing deal is representing.

The companies the Fund will invest in are typically acquisition targets for biopharmaceutical multinationals, which are known for their constant hunger to fill their pipelines.

Investment decisions are based on fundamental company analyses of the company's technology and/or products, product development risks, market entry barriers, competition, financials and the expected market development. But maybe even more important by making serious efforts to understand the strengths and weaknesses of management and their view on the future of the company and the markets they serve.

The Fund may, if the Fund Manager has a good reason to do so, hold a substantial percentage of the Fund in cash. It can make limited use (no more than 10% of the Net Asset Value) of borrowed money:

- to bridge temporary liquidity shortages;
- to make use of one or more investment opportunities in anticipation of new subscription orders coming into the Fund from Unit Holders.

For the most important investment criteria we refer to page 16 of the Prospectus.

Aescap Life Sciences

Risk control

The portfolio of companies is expected to consist of a limited number of approximately 18 companies. It is this 'cherry picking' from a basket of over 750 listed companies in this sector which should drive the outperformance of the different biotech indexes / trackers. In order to reduce the risks of investing in this sector the Fund will diversify its portfolio over several disease areas, different phases of product development as well as geographical areas.

Risk Profile

Investing in biotech companies involves a high degree of risk and prices of the securities of such companies, especially of companies with a small market cap, may be volatile. Furthermore, there is concentration risk because of the biotech focus and a relatively small portfolio of approximately 20 companies. Investments are also often made in a foreign currency like the US dollar and foreign currency exposures are not hedged back to the Euro, the base currency of the Fund. Please see Section 5 of the Prospectus for an overview of all risk factors in relation to (an investment in) the Fund.

For investment criteria and investment restrictions as well as the Fund characteristics and investor profile more in detail we refer to section 4 of the Prospectus.

Most important risks and uncertainties

A Unit Holder cannot lose more than the amount invested in the Fund by that Unit Holder.

The most important risks, which must be considered that are common with an investment fund of this nature, involved in investing in the Fund

Volatility risk

There are financial risks involved with investing in Units of the Fund. Unit Holders have to realize that the stock market value of underlying investments of the Fund may significantly fluctuate, especially in the biotech / life sciences market where governmental regulations and/or technology risks can have a significant impact on a company's value. As a result of fluctuations of the biotech / life sciences stock markets, the Net Asset Value of the Fund may also fluctuate, which means that it is possible that Unit Holders, when redeeming, may not receive the full amount invested in the Fund.

Market risk

Markets may rise and fall and the prices of financial instruments and other assets on the financial markets can rise and fall. In general, and more specifically the prices of assets of the nature and type the Fund may invest in and hold, can rise and fall. A careful selection and spread of investments does not provide any guarantee of positive results. In the biotech / life sciences market governmental measures related to medicine approvals and pricing as well as technology risks can have a large impact on the value of one single company or the market as a whole. There may be various reasons why markets fall like recessions caused by a change in the economic business cycle or a pandemic.

Currency risk

The Fund does not hedge currency positions. Investments other than in Euros can therefore cause fluctuations, positive as well as negative, in the Net Asset Value of the Fund.

Risk that investments do not develop as expected

The Fund aims for an average yearly mid-term minimum net return of 20% per annum, after deduction of all costs. There is however no guarantee that this return will be achieved. Moreover, no guarantee can be given that the analyses of the Fund Manager concerning the expected development of the portfolio of companies are correct.

Risks related to the sector the Fund invests in

The sector the Fund is investing in comes with certain specific risks such as:

- Potential weakening of the patent protection environment in one or more jurisdictions;
- Financing risk, given the fact that many biotech companies are loss making and therefore are in need of further financing to develop their products;
- Major technology breakthroughs outside of the Fund's portfolio;
- Legal or regulatory developments influencing the life sciences industry and/or the investments made by the Fund;
- Changes in projections by securities analysts of a company;
- Biotech stock market fluctuations;

Risks of a general economic and political nature

Investments made by the Fund are subject to general economic risks, for instance, reduced economic activity, rising interest rates, inflation and rising prices of commodities. The value of the Fund can also be influenced by political developments, wars and other global trends and events.

Aescap Life Sciences

Concentration risk

Because of the limitation of investments to approximately 20 different companies, there may be stronger fluctuations in the Net Asset Value of the Fund in case one or more particular investments by the Fund would decrease in value, than it would normally be the case if the investments were more spread. As a result of the strategy of the Fund, the returns of the Fund can deviate significantly from the returns of a world equity index. As a consequence thereof, specific risks arise that are reflected in differences in performance between the Fund and the global equity indices, positively and negatively.

Systemic risk

Certain events in the world or certain activities from one or more important parties in the financial markets can lead to a disturbance in the normal functioning of the financial markets. As a result of this, substantial losses may arise, caused by liquidity and counterparty risks following from such a disturbance.

Cyber Security risk

The Unit Holders are exposed to the risk of a cyber attack or data breach at the level of the Fund Manager or at the level of the service providers. The Fund Manager and service providers have implemented measures to mitigate this risk as much as possible.

Inflation risk

There may be a risk that the purchasing power of the amount invested by the Unit Holder in the Fund decreases as a result of inflation.

Risk of limited redemption

Units can only be transferred to the Fund (except for transfers to persons that are next of kin or direct in law of a Unit Holder). The Fund is in principle obliged to purchase Units twice a month, on a Transaction Day. Under certain circumstances the Fund Manager is authorized to delay redemption or honor redemption requests only partially (see Section 15 of the Prospectus: "Redemption"). In those cases the Unit Holder is not able to redeem, or redeem only partially, its Units. This may (also) have a negative effect on the price of the Units.

Indemnification risk

The Fund Manager and the Legal Owner are entitled to be indemnified out of the Fund Assets against costs, losses and expenses which they may incur or become liable in connection with the execution of their duties. In addition, the Depositary, the Administrator and other service providers also are entitled to an indemnity under the terms of their respective agreements for the services they provide. These obligations could require substantial indemnification payments out of the Fund Assets, provided however that the Depositary shall not be so indemnified with respect to any matter resulting from its negligent or intentional failure to properly fulfil its obligations in accordance with article 21(12) of the AIFM Directive, and no other person shall be so indemnified with respect to any matter resulting from its attributable breach (toerekenbare tekortkoming in de nakoming).

Counterparty risk

The Fund will be subject to the risk of the inability or refusal of payment or clearing institutions, principals or other service providers or other counterparties to its transactions, to perform or to perform in time under such services or transactions. Any such failure, refusal or delay, whether due to insolvency, bankruptcy or other causes, could subject the Fund to substantial losses. The Fund Manager will seek to mitigate these risks by reviewing the creditworthiness and reliability of all service providers and counterparties and only entering into transactions with those parties that the Fund believes to be creditworthy and reliable.

Liquidity risk

If, due to unforeseen circumstances, normal liquidity conditions do not apply, the Fund could face liquidity risk. This could imply that financial instruments cannot be sold or bought under normal market conditions, leading to significant direct and indirect transaction costs. It may also mean that positions cannot be sold at the anticipated price as established and deemed to be the fair value at the date of deciding to liquidate/sell those positions. This may have a negative effect on the Net Asset Value of a Unit.

Settlement risk

This is the risk that settlement through a payment system does not take place as expected, because the payment or delivery of the financial instruments by a counter party does not take place, or does not take place on time, or is not as expected.

Risk of change in (fiscal) laws

This is the risk that fiscal legislation changes or that new legislation comes into force that negatively affects the fiscal treatment of Fund or its Unit Holders.

Key man risk

Patrick Krol has been assigned by the Fund Manager as Portfolio Manager of the Fund. Unit Holders are exposed to the risk that Patrick Krol ceases to be involved with the Fund Manager.

Regulatory supervision and compliance risk

The regulatory rules keep evolving and changes therein may adversely affect the functioning of the Fund and/or the Fund Manager's ability to pursue the investment policy for the Fund.

Unclear rules and regulations and conflicting advice may result in a breach of rules and regulations applicable to the Fund, Resulting fines and other sanctions and possible damage to the reputation of the Fund, the Fund Manager and other connected persons may result in a negative impact on the Net Asset Value of the Fund and the Units.

Aescap Life Sciences

Operational risk

There is a risk that the internal processes, people and systems of the Fund Manager fail, which may have a negative effect on the business continuity of the Fund Manager and its ability to pursue the investment policy.

Legal Owner

The Legal Owner of the Fund is Stichting Life Sciences, having its office at Hoogoorddreef 15, 1101 BA Amsterdam. The Legal Owner is a foundation established under the laws of The Netherlands on 17 August 2011 in Amsterdam, which is registered in the Trade Register at the Chamber of Commerce in Amsterdam under number 65423046. The Legal Owner's only statutory purpose is to act as Legal Owner of the Fund and to protect the interests of the Unit Holders. It will have access to all reports from the Administrator.

The most important task and power of the Legal Owner is to act as legal owner of the Fund Assets and incur and/or assume the Fund Obligations on behalf and for the account and risk of the Unit Holders.

Fund Manager

The Fund will be managed by Privium Fund Management B.V. as Alternative Investment Fund Manager of the Fund. The Fund Manager is responsible for the entire management of the Fund in accordance with the provisions of the Fund Documents and applicable laws. The Fund Manager is also responsible for maintaining records and furnishing or causing to be furnished all required records or other information of the Fund to the extent such records, reports and other information are not maintained or furnished by the Administrator, the Legal Owner, the Depositary or other service providers.

Privium Fund Management B.V. is a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands having its official seat (zetel) in Amsterdam, the Netherlands and its principal offices at Symphony Towers 26/F, Gustav Mahlerplein 3, 1082 MS Amsterdam, the Netherlands. The Fund Manager is registered in the Dutch trade register (handelsregister) under file number 34268930.

The Fund Manager performs its services in accordance with the Prospectus. Pursuant to the Prospectus the Fund Manager has the full and exclusive power, discretion and authority to invest and manage the assets of the Fund.

The statutory management board (bestuur) of the Fund Manager consists of Mr C.H.A. Heijman and Mr M. Baak who are the (daily) policy makers of the Fund Manager.

The Fund Manager holds an AIFM license issued by the AFM within the meaning of article 2:65(a) FSA and is subject to conduct of business and prudential supervision by the AFM and DNB respectively.

The most important tasks and powers of the Fund Manager are the following:

- to determine and execute the investment policy of the Fund;
- to check the administration of the Fund executed by the Administrator;
- to see the Administrator determines the Net Asset Value for the Fund and for each Unit Class and Series correctly and on time;
- to ensure that the Fund complies with the relevant regulations and reporting obligations;
- to ensure that the Fund complies with the defined risk management framework as further described briefly below;
- generally to observe the interests of the Unit Holders in accordance with the Prospectus.

For details relating to delegation of Fund Manager's duties, resignation and removal of the Fund Manager, liability of the Fund Manager, Indemnification, Insurance as well as other Funds managed by the Fund Manager we refer to section 6 of the Prospectus.

The Portfolio Manager

The portfolio of the Fund is managed by Mr. Patrick J.H. Krol who is supported by several analysts. Additionally, advisors and industry/medical experts may be used. The advisors and industry/medical experts will not provide any investment advice for which an investment advisory license is needed but may be asked to provide their knowledge on a certain disease, medicine, market segment, etc. The advisors or industry/medical experts will not make any investment decisions either.

Patrick Johan Hendrik Krol (1963), Founder and Portfolio Manager

Patrick Krol is a biotech investment and business development specialist. Patrick joined biotech venture capital fund Aescap 1 as an Investment Partner at its start in 2005 and in 2009 became the fund's Managing Partner. In 2015 he took over the Aescap name to launch Aescap Life Sciences, a fund for joint account investing in public biotech companies based on Patrick's successful track record as a private investor in public biotech. From 1995 to 2005, Patrick guided over 35 public pharma and biotech companies to successfully launch or grow their products. As a Founder and Managing Director at consultancy company Firm United Healthcare from 1997 to 2004, Patrick was responsible for growing the company to become a market leader. During this period, he also co-founded Interactive Healthcare and the Healthcare Management School. In 2004 he sold his share in all three companies to become a biotech investment professional. Since 2004 he has gained experience on board level in the life sciences sector as the chairman of the supervisory boards of i-Optics B.V. and to-BBB technologies B.V. and as a Non-Executive Director of Aquapharm Biodiscovery Ltd, EasyScan Holding BV, Cassini Holding BV, and Shire International Licensing BV (a subsidiary of top-20 biopharma company Shire Plc), and as a supervisory director of F-Star GmbH, F-Star Alpha Ltd, F-Star Beta Ltd, F-Star Gamma Ltd, F-Star Delta Ltd and Orphazyme Aps. In 2003, he became a visiting teacher of the business school of the University of Wageningen teaching 'Strategy in the pharmaceutical Industry'. He published several articles on biopharma marketing and communications strategy and has been a speaker and moderator at life sciences seminars and congresses. Patrick studied physical therapy followed by business economics and later in his career concluded an M.B.A. in Executive Management and Consultancy at LMS.

Key Person

Patrick Krol will be the Key Person of the Fund and a Key Person Event means the situation occurring when the Key Person ceases to be actively involved in the business and affairs of the Fund as a Portfolio Manager. The Fund Manager shall without delay give notice to the Investor Advisory Committee and the Unit Holders of the occurrence of a Key Persons Event. In case of a Key Person Event the Portfolio Advisors and Investor Advisory Committee, in consultation with the Fund Manager and the Legal Owner, will decide on how to continue with the Fund or potentially how to liquidate the portfolio of the Fund and put it to an end.

Aescap Life Sciences

Administrator

IQ EQ Financial Services B.V. established in Amsterdam, The Netherlands, has been appointed as the administrator.

The most important tasks of the Administrator, under responsibility of the Fund Manager, are:

- conducting the financial and investment administration of the Fund;
- calculating the Net Asset Value of the Fund and for each Unit Class and Series; and
- keeping the register of Unit Holders of the Fund.

Depositary

Darwin Depositary Services B.V. established in Amsterdam, The Netherlands, has been appointed as the depositary.

The most important tasks of the Depositary are:

- safekeeping of financial instruments in which the Fund has invested;
- ensuring that the Fund Manager acts in accordance with the Investment Policy; and
- monitoring of cash flows in respect of the Fund and ensuring that issue and redemption of Units and determination of the Net Asset Value is performed correctly.

The actual safekeeping of the financial instruments in which the Fund has invested is delegated to the Custodian. The depositary has assigned Saxo Bank Nederland (previously BinckBank N.V.) as Custodian.

Depositary agreement

The Fund Manager and Depositary have concluded an agreement (the 'Depositary Agreement') setting out the duties of the Depositary and what the Fund Manager must do to enable the Depositary to perform those duties duly.

Unit Holders

The Unit Holders are jointly economically entitled (each proportionally, taking into account the Series they form part of, according to the number of Units owned) to the net assets of the Fund. The combined assets of the Unit Holders invested in the Fund are intended for collective investment and for their own account and risk. (See Section 12 of the Prospectus, "Unit Holders").

Contractual arrangement between Unit Holders, Fund Manager and Legal Owner

The Fund being the contractual arrangement between Unit Holders, the Fund Manager and the Legal Owner is governed by the Prospectus.

Voting in meetings of shareholders of companies in which the Fund invests

The Fund Manager is supposed to have at its disposal the shares and the voting rights attached thereto that the Legal Owner holds. In principle, the Fund Manager will use the voting rights attached to the shares held by the Fund. The Fund Manager will use these voting rights in such manner that can be conducive to realizing the Fund's investment objective. There is no obligation for the Fund Manager to use its voting rights.

Amsterdam, 30 July 2021

Privium Fund Management B.V.

Aescap Life Sciences

Risk management

Privium Fund Management B.V. has a clear and elaborate Risk Management framework, in line with current legislation, such as the Alternative Investment Fund Manager Directive (AIFMD). The Risk Management function within Privium is performed by an independent Risk Manager. Privium has a Risk Management Committee which meets at least on a monthly basis.

The Risk Management framework consists of several individual components, whereby Risk Monitoring is being performed on an ongoing basis.

Under the AIFM Directive, the Fund Manager is required to establish and maintain a permanent risk management function. This function should have a primary role in shaping the risk policy of each Alternative Investment Fund ("AIF") under management by the Fund Manager, risk monitoring and risk measuring in order to ensure that the risk level complies on an ongoing basis with the AIF's risk profile.

The risk management function performs the following roles:

- Implement effective risk management policies and procedures in order to identify, measure, manage and monitor risks;
- Ensure that the risk profile of an AIF is consistent with the risk limits set for the AIF;
- Monitor compliance with risk limits; and
- Provide regular updates to senior management concerning:
 - 1: The consistency of stated profile versus risk limits;
 - 2: The adequacy and effectiveness of the risk management process; and
 - 3: The current level of risk of each AIF and any actual or foreseeable breaches of risk limits.

As described by the AIFM Directive quantitative risk limits are, where possible, constructed for various risk categories: market risk, liquidity risk, credit risk, counterparty risk and operational risk. These risk limits should be in agreement with the risk profile of the fund.

The risk management function is fully independent from the portfolio management function of the Fund Manager. The risk manager has full authority to close positions or the authorization to instruct the closing of positions on his behalf in case of a risk breach.

To ensure that all risk management tasks are executed correctly and timely, the Fund Manager uses an automated system that registers all risk tasks, keeps a list of all pending risk tasks, and escalates risk tasks that have not been executed or report a violation of a risk rule. The system produces an audit log that can be verified by the internal auditor, the external auditor, the management board, the regulator or other stake holders. Not all risk variables have limits but to identify any new relevant risks, every variable that is reported in the system flows through a sanity check. The sanity check will raise an exception if the variable falls outside its "normal" boundaries. The Risk Manager is notified of these exceptions and will make an assessment whether the situation is stable or whether further escalation is needed.

The positions of the fund are administered and reconciled by using a professional portfolio management system. Risk reports such as Value at Risk and Stress Scenarios are run using Bloomberg.

The Fund Manager uses an API-based system in which positions and/or risk exposures are synced from the Portfolio Manager's Excel (or alternative software) to a central database.

The CM system is responsible for monitoring of the pre-defined risk limits. The limits can either be configured as notification limits, soft limits or hard limits. In case of a breach of any of the limits, the escalation procedures are followed as described in the Risk Management Procedures (Annex 17) of the Privium Handbook.

The reoccurring risk tasks are:

- Weekly risk report by risk management, including Value at Risk.
- Monthly reporting by portfolio management
- Quarterly Operational risk management
- Monthly stress scenarios. On ad hoc basis extra stress scenarios can be done.

On a monthly basis the Risk Committee of the Fund Manager meets to discuss the performances and risks of the Fund. Any breaches are discussed. On a yearly basis a Risk Evaluation and Product Review is conducted.

In 2016 Privium's senior management team decided to engage an external party in the annual evaluation of the internal processes. This audit primarily focusses on risk management and compliance processes. In Q4 2020 this audit was executed for the fifth time and the findings were reported to Privium's management. The audit did not demonstrate any material deviations.

Aescap Life Sciences

Financial Statements

Semi Annual Report as per June 30, 2021

Aescap Life Sciences**Balance Sheet as per June 30, 2021**

(before profit appropriation)

Notes	30-06-21		31-12-20	
	EUR	EUR	EUR	EUR
Investments				
Securities	4	193,130,683	206,772,567	
				206,772,567
Receivables and current assets				
Cash at Banks	5	7,161,727	4,086,827	
Dividends receivable		20,024	-	
Other assets	6	17,279	24,293	
		7,199,030		4,111,120
Total Long Term and Current Assets				
		200,329,713		210,883,687
Current Liabilities (Due within One Year)				
Payables to the Fund Manager	7	263,378	286,551	
Payables for administration-, custodian- depository- and legal ownerfees	7	8,117	18,014	
Payables to Unit Holders	7	956,000	86,251	
Other payables	7	15,767	775,000	
			24,797	
Total Current Liabilities				
		1,243,262		1,190,613
Total of Receivables and Current Assets				
Less Current Liabilities				
		5,955,768		2,920,507
TOTAL ASSETS LESS CURRENT LIABILITIES				
		<u>199,086,451</u>		<u>209,693,074</u>
Investors' equity				
Issued capital	8.1	138,661,613		146,155,110
Other reserve	8.2	63,513,671		65,099,026
Legal reserve	8.3	17,279		24,293
Undistributed result current year	8.4	(3,106,112)		(1,585,355)
TOTAL INVESTORS' EQUITY				
		<u>199,086,451</u>		<u>209,693,074</u>

Aescap Life Sciences**Profit & Loss Account for the period January 1, 2021 – June 30, 2021**

	Notes	01-01-21 / 30-06-21		01-01-20 / 30-06-20	
		EUR	EUR	EUR	EUR
Direct Income from Investments					
Dividends	9.1	107,415		-	
Interest Income	9.2	(21,432)		18,280	
			85,983		18,280
Indirect Income from investments					
Unrealised Price Gains/Losses on Investments	10.1	2,115,758		(18,820,303)	
Unrealised Currency Gains/Losses on Investments		6,623,503		(849,686)	
Realised Price Gains/Losses on Investments	10.2	(7,763,251)		19,248,834	
Realised Currency Gains/Losses on Investments	10.3	(2,453,805)		569,258	
			(1,477,795)		148,103
Other Income					
Exchange Differences on Cash (including FX)		331,307		(281,442)	
Subscription and redemption fees	9.3	39,771		25,274	
			371,078		(256,168)
Total income			(1,020,734)		(89,785)
Expenses					
Management Fee	11.1	1,263,471		1,076,699	
Performance Fee	11.1	701,203		2,377,017	
Administration Fee	11.2	61,006		53,136	
Audit Fee	11.2	8,970		8,995	
Custodian, Depository and Legal Owner Fee	11.2	31,457		26,720	
Other Expenses	11.2	19,271		21,525	
			(2,085,378)		(3,564,092)
Depreciation					
Amortization of intangible fixed assets	6	7,014		7,014	
			(7,014)		(7,014)
Total expenses			(2,092,392)		(3,571,106)
NET PROFIT FOR THE BOOKYEAR			<u>(3,113,126)</u>		<u>(3,660,891)</u>
COMPREHENSIVE INCOME			<u>(3,113,126)</u>		<u>(3,660,891)</u>

Aescap Life Sciences**Statement of Cash Flows for the period January 1, 2021 – June 30, 2021**

	01-01-21 / 30-06-21		01-01-20 / 30-06-20	
	EUR	EUR	EUR	EUR
Cash Flow from Investing Activities				
Total Investment Result		(3,113,126)		(3,660,891)
Realised Price and Currency Results	9,885,749		(19,536,650)	
Unrealised Price and Currency Results	(8,739,261)		19,669,989	
Amortization of intangible fixed assets	7,014		7,014	
Purchase of Investments	(68,465,532)		(86,384,724)	
Sales of Investments	80,629,622		83,655,689	
Change in Short Term Receivables	(20,024)		-	
Change in Current Liabilities	52,648		(3,672,555)	
		13,350,216		(6,261,237)
Net Cash Flow from Investing Activities		10,237,090		(9,922,128)
Cash Flow from Financing Activities				
Subscriptions	12,413,737		25,518,656	
Redemptions	(19,907,234)		(8,101,788)	
Net Cash Flow from Financing Activities		(7,493,497)		17,416,868
Net Cash Flow		2,743,593		7,494,740
Exchange Differences on Cash		331,307		(281,442)
Change in Cash at banks		3,074,900		7,213,298
Change in Cash at banks				
Cash and Cash Equivalents at the Start of the reporting period		4,086,827		25,799,505
Cash and Cash Equivalents at the End of the reporting period		7,161,727		33,012,803
Change in Cash at banks		3,074,900		7,213,298

Aescap Life Sciences

Notes

1. General

The Fund is a mutual Fund ("fonds voor gemene rekening") under the laws of the Netherlands. It does not have legal personality.

The Fund's financial year runs from January 1 up to and including December 31. The financial statements will be made up in accordance with Title 9 of Book 2 of the Dutch Civil Code. The financial statements are reported in Euros and are published within four (4) months after the end of the financial year. The financial statements consists of a report from the Fund Manager together with the annual accounts. The annual accounts consist of the balance sheet, the profit and loss account and the explanation thereof. The explanation will include at least an overview of the evolution of the Fund's value over the financial year and the composition of the investments of the Fund at the end of the financial year concerned. The annual accounts are audited by Mazars N.V., whereas these semi annual accounts did not have had an audit by the independent auditor. The financial statements shall be made available to the Unit Holders via email.

The Fund started its activities as per March 28, 2016.

Tax Position of the Fund

Corporate income tax

The Fund is tax transparent for Dutch corporate tax purposes, as a consequence of which the Fund is not subject to Dutch corporate income tax. From a Dutch tax perspective, the returns on the investments received by the Fund directly influence the tax position of the Unit Holder.

Withholding taxes

Distributions by the Fund are not subject to Dutch dividend withholding tax as a consequence of its transparency for tax purposes. Due to its transparency, the Fund itself is not entitled to any credit or refund of Dutch dividend withholding tax or (non-reclaimable) foreign withholding taxes withheld on dividends and interest received, nor can the Fund claim any benefits under a tax treaty concluded by the Netherlands with other states.

The tax transparency of the Fund also implies that any dividend withholding tax and foreign withholding taxes withheld on its investments are allocated to the Unit Holders, i.e., on a pro rata basis. In principle, such withholding taxes may be set off by the Unit Holders, whereby the conditions that apply are the same as would be the case for a direct investment (pro rata) by the relevant Unit Holder.

For the reporting period the fund did not receive any (withholding)tax refunds.

2. Principles of Valuation

2.1 Valuation of assets and liabilities

The assets and liabilities of the Fund will be valued in accordance with the following policies and principles:

Securities stated as investments are initially recognized at fair value plus directly attributable transaction costs. Subsequently these securities are stated against fair value. Gains and losses arising from fair value changes are taken to the profit and loss account.

Securities

– listed securities (shares) will be stated against fair value at initial recognition and subsequently stated at fair value. The fair value is determined at the last official traded price ("closing price") of the Business Day preceding the Valuation Day (or, if a stock exchange was not open for business, the previous Business Day).

– warrants are initially valued at fair value. The fair value is determined at the last official traded price and if not available warrants will be valued at a theoretical valuation model such as Black & Scholes.

Other assets and liabilities

– liquidities and deposits which are immediately payable are valued at amortized cost.

– assets and liabilities in a foreign currency will be converted into Euro at the exchange rate on the last Business Day preceding the Valuation Day.

– other assets and liabilities are valued at their nominal value.

Expenses related to the purchase of investments are included in the cost of investments. Sales charges, if any, are deducted from gross proceeds and will be expressed in the capital gain/losses.

2.2. Foreign Currency Translation

Assets and liabilities in foreign currencies are translated into EUR at the rate of exchange as at the balance sheet date. All exchange differences are taken to the profit and loss account. Income and expenses in foreign currencies are translated at the exchange rate as per transaction date.

Rates of exchange used in this final report as at June 30th, 2021 (December 31st, 2020) :

	30-06-21	31-12-20
EUR / DKK	7.4361	7.4416
EUR / GBP	0.8571	0.8940
EUR / SEK	10.1379	10.0498
EUR / USD	1.1858	1.2217

Aescap Life Sciences

Notes (continued)

2.3 Other Assets and Liabilities

Other assets and liabilities are recorded at fair value and then valued at amortised cost.

2.4 Income Recognition Principles

The result is determined by deducting expenses from the proceeds of dividend, interest and other income in the period under review. The realised revaluations of investments are determined by deducting the purchase price from the sale proceeds. The unrealised revaluations of investments are determined by deducting the purchase price or the balance sheet value at the start of the period under review from the balance sheet value at the end of the period under review. Brokerage fees payable on the acquisition of investments, if any, are considered to be part of the investments costs, and as a result, are not taken to the profit and loss account.

2.5 Cash Flow Statement

The cash flow statement is prepared according to the indirect method. The presentation of the cash flow is derived from the investment result. In accordance with RJ 615.310 the cash flow statements consists of cash flows from investing and financing activities.

Cash flows in foreign currencies during the year are translated at the exchange rate prevailing at the transaction date. Exchange rate differences are separately included in the cash flow statement between the net cash flow and the change in cash.

2.6 Subscription and Redemption of Units

2.6.1 Subscription

Currently the Fund is offering the following Unit Classes to Unit Holders:

- AEscap Life Sciences Manager: Minimum investment is EUR 100,000
- AEscap Life Sciences Investors: Minimum investment is EUR 500,000
- AEscap Life Sciences Investors <500k: Minimum investment is EUR 101,100
- AEscap Life Sciences Investors 10M+: Minimum investment is EUR 10,000,000
- AEscap Life Sciences Investors 20M+: Minimum investment is EUR 20,000,000
- AEscap Life Sciences Investors 30M+: Minimum investment is EUR 30,000,000
- AEscap Life Sciences Investors N: Minimum investment is EUR 500,000

The Fund Manager can accept a lower minimum subscription amount for the Aescap Life Sciences Investors Unit Class and the Aescap Life Sciences Investors <500k Unit Class. This minimum can be lowered to EUR 10,000. Here clients of wealth managers, family offices or private banks, who have an executed discretionary portfolio agreement or investment advisory services agreement with the wealth manager, family office or private bank, are accepted when the investment decision to invest in the Aescap Life Sciences is taken or advised by the wealth manager, family office or private bank. This will only be possible for the Life Sciences Investors Unit Class. Additionally, for family members (being defined as first and second degree relatives) of existing Unit Holders, subscription amounts below EUR 101,000 can be accepted as well. Here the subscription will be linked to the size of the current investment of the existing Unit Holder. This will both be possible for the Aescap Life Sciences Investors Unit Class and the Aescap Life Sciences Investors <500k Unit Class.

Existing Unit Holders can make applications for further Units in amounts of € 10,000 or more.

Issue of Units

The Fund may issue new Units of a particular Unit Class on each Transaction Day at the Net Asset Value per Unit in such Unit Class on the preceding Valuation Day. Here a subscription fee of 1% will be applied (Aescap Life Sciences Investors <500k). This fee is for the benefit of the Fund Manager and may be used to cover expenses like, among potential other expenses, any marketing expenses and/or any placement agent fees following the issue. Units will be issued for the remaining amount in the Series applicable on the Transaction Day. The Units shall be issued in Amsterdam.

Subscription requests (latest 1 business day prior to the Transaction Day)

Applications for the subscription of Units should be submitted to the Administrator latest one Business Day prior to the desired Transaction Day. In order to subscribe, a subscription form must be filled out. The subscription request should indicate the amount for the size of subscription which is requested.

Payment (latest 1 business day prior to the Transaction Day)

Payment is possible only through a bank account in the name of the Unit Holder. The subscription amount must be received in the account of the Legal Owner ultimately one Business Day prior to the relevant Transaction Day. No interest will be paid over the subscription amount for the period between the payment of the subscription amount and the issuance of Units. The interest which is accrued is for the benefit of the Fund. If the amount and/or forms are not received within the required timeframe, the subscription will take effect at the first business day of the following month. The Fund will make no adjustment or compensation for interest received over this period.

Aescap Life Sciences

Notes (continued)

2.6.2 Redemption

Unless redemption is suspended (see "Suspension of redemption" below), the Fund will accept redemptions of Units on each Transaction Day at the Net Asset Value thereof in the applicable Series on the preceding Valuation Day (the "redemption value"), after deducting an anti-dilution levy of 0.2% of the redemption sum (and if, applicable an early redemption fee). The anti-dilution levy is to cover the transaction and other costs made in connection with the redemption and will be for the benefit of the Fund. This fee will be deducted from the amount to be received by the Unit Holder.

Redemption requests

Redemption requests have to be received by the Fund Manager at least twenty (20) Business Days before the desired Transaction Day. The redemption request should indicate the amount in number of Units, up to four (4) decimals, for which redemption is requested. Partial redemption is only allowed if after redemption the Unit Holder is still holding Units with an aggregate Net Asset Value of at least € 100,000. The Fund Manager will check this upon receiving the redemption request. The Net Asset Value of the Units offered for redemption needs to amount to at least € 10,000.

To request for redemption, Unit Holders must use a special form, which can be downloaded from the Website.

Payment redemption amount

Redemption sums (Net Asset Value per Unit minus redemption fee and, if applicable, early redemption fee) will be paid within ten (10) Business Days of redemption to the bank account of the Unit Holders as mentioned in the register of Unit Holders. Payment on this bank account constitutes a discharge of the Fund towards the respective Unit Holder of the obligation to pay the redemption amount.

3. Financial instrument risk factors

Financial instrument risk management

The Fund and its manager has adequate risk management policies, procedures and systems in order to identify, measure, manage and monitor all risks that are relevant to the investment strategy and to which Aescap Life Sciences is or may be exposed. The Manager has highly qualified staff in control functions which operate independently from the investment professionals. The Risk Manager performs an analysis of the governance, adequacy and effectiveness of risk limits, reporting and follow-up procedures on a regular basis. In addition, the Depositary of the Fund independently performs several checks regarding ownership of assets, valuations and cash flows from and to investors.

For the risk management and willingness to take risks disclosures we refer to the management report.

Fair value risk

The fund is not exposed to fair value risk whereas all financial instruments are valued at fair value.

Credit risk

The fund does not invest in any fixed income instruments resulting in no exposure to credit risk.

Find below the risks, the fund is exposed to, which may have direct impact on the valuation of the funds' financial instruments :

Market risk

Markets may rise and fall and the prices of financial instruments and other assets on the financial markets in general, and more specifically the prices of assets of the nature and type the Fund may invest in and hold, can rise and fall. A careful selection and spread of investments does not provide any guarantee of positive results. In the biotech / life sciences market governmental measures related to medicine approvals and pricing as well as technology risks can have a large impact on the value of one single company or the market as a whole.

Currency risk

The Fund does not hedge currency positions. Investments other than in Euros can therefore cause fluctuations, positive as well as negative, in the Net Asset Value of the Fund.

Risks related to the sector the Fund invests in

The sector the Fund is investing in comes with certain specific risks such as:

- Potential weakening of the patent protection environment in one or more jurisdictions;
- Financing risk, given the fact that many biotech companies are loss making and therefore are in need of further financing to develop their products;
- Major technology breakthroughs outside of the Fund's portfolio;
- Legal or regulatory developments influencing the life sciences industry and/or the investments made by the Fund;
- Changes in projections by securities analysts of a company;
- Biotech stock market fluctuations.

Concentration risk

Because of the limitation of investments to approximately 20 different companies, there may be stronger fluctuations in the Net Asset Value of the Fund in case one or more particular investments by the Fund would decrease in value, than it would normally be the case if the investments were more spread. As a result of the strategy of the Fund, the returns of the Fund can deviate significantly from the returns of a world equity index. As a consequence thereof, specific risks arise that are reflected in differences in performance between the Fund and the global equity indices, positively and negatively.

Liquidity risk

If, due to unforeseen circumstances, normal liquidity conditions do not apply, the Fund could face liquidity risk. This could imply that financial instruments cannot be sold or bought under normal market conditions, leading to significant direct and indirect transaction costs. It may also mean that positions cannot be sold at the anticipated price as established and deemed to be the fair value at the date of deciding to liquidate/sell those positions. This may have a negative effect on the Net Asset Value of a Unit.

Especially when the Fund will experience substantial redemption requests the Fund may be exposed to a great extent to this risk.

Aescap Life Sciences**8.5 Investors' equity
(Fund Net Asset Value)**

	Net Asset Value per unit	number of units	Investors' equity	
			30-06-21	31-12-20
Aescap Life Sciences Fund management	2,863.5633	11,342.5267	32,480,043	32,252,252
Aescap Life Sciences Investors	2,160.1228	66,933.0375	144,583,580	120,399,327
Aescap Life Sciences Investors 011117	-	-	-	-
Aescap Life Sciences Investors 011217	-	-	-	-
AescapLife Sciences Investors 011118	-	-	-	2,825,159
Aescap Life Sciences Investors 011218	-	-	-	1,867,537
Aescap Life Sciences Investors 010320	-	-	-	944,480
Aescap Life Sciences Investors 010420	-	-	-	1,693,490
Aescap Life Sciences Investors 010520	-	-	-	901,973
Aescap Life Sciences Investors 010620	-	-	-	1,848,974
Aescap Life Sciences Investors 010720	-	-	-	3,697,456
Aescap Life Sciences Investors 010820	-	-	-	910,278
Aescap Life Sciences Investors 010920	-	-	-	271,462
Aescap Life Sciences Investors 01020	-	-	-	1,266,442
Aescap Life Sciences Investors 011120	-	-	-	2,610,739
Aescap Life Sciences Investors 011220	-	-	-	4,548,210
Aescap Life Sciences Investors 150320	-	-	-	257,946
Aescap Life Sciences Investors 150420	-	-	-	1,121,250
Aescap Life Sciences Investors 150520	-	-	-	4,286,759
Aescap Life Sciences Investors 150620	-	-	-	422,626
Aescap Life Sciences Investors 150720	-	-	-	660,288
Aescap Life Sciences Investors 150820	-	-	-	1,051,911
Aescap Life Sciences Investors 150920	-	-	-	352,754
Aescap Life Sciences Investors 151020	-	-	-	92,253
Aescap Life Sciences Investors 151120	-	-	-	-
Aescap Life Sciences Investors 151220	-	-	-	19,852,798
Aescap Life Sciences Investors 10M+	2,200.5532	6,025.8724	13,260,253	5,556,710
Aescap Life Sciences Investors 20M+	-	-	-	-
Aescap Life Sciences Investors 20M+ 150920	-	-	-	-
Aescap Life Sciences Investors 1321	2,147.9128	11.9348	25,635	-
Aescap Life Sciences Investors 1421	2,142.0653	1,406.8225	3,013,506	-
Aescap Life Sciences Investors 1521	2,138.6706	457.8220	979,130	-
Aescap Life Sciences Investors 15321	2,154.6850	1,188.2366	2,560,276	-
Aescap Life Sciences Investors 15421	2,134.4061	369.5791	788,832	-
Aescap Life Sciences Investors 15521	2,108.0309	206.5161	435,342	-
Aescap Life Sciences Investors 15621	2,160.1228	434.6017	938,793	-
Aescap Life Sciences Investors 1621	2,124.5872	9.9129	21,061	-
Total Shareholders' Equity (Fund Net Asset Value)			199,086,451	209,693,074

Subsequent events (events after the balance sheet date)

No relevant subsequent events did occur after balance sheet date.

Aescap Life Sciences

Notes to the Profit & Loss Account

9. Income from Investments

9.1 Dividends

This refers to net cash dividends including withholding tax.

9.2 Interest Income

This amount was received / paid on outstanding cash balances.

9.3 Other Income

This refers to the charges received on units issued and repurchased. These costs are to cover transaction costs in relation with the purchase and sale of units and are booked as an income for the Fund.

10. Capital gains / losses

10.1 Unrealised price gains / losses on investments

This refers to unrealised gains on securities € 72,155,522 (halfyear 2020: € 22,147,894) and unrealised losses on securities – € 70,039,764 (halfyear 2020 : – € 40,968,197)

10.2 Realised price gains / losses on investments

This refers to realised gains on securities € 8,561,633 (halfyear 2020 : € 28,148,175) and realised losses on securities – € 16,324,884 (halfyear 2020 : – € 8,899,341).

10.3 Realised currency gains / losses on investments

This refers to realised gains on securities € 230,507 (halfyear 2020 : € 613,257) and realised losses on securities – € 2,684,312 (halfyear 2020 : – € 43,999).

11. Expenses

11.1 Management Fees

(1) Management Fee

(2) Performance Fee

	01-01-21 / 30-06-21	01-01-20 / 30-06-20
	1,263,471	1,076,699
	701,203	2,377,017
	<u>1,964,674</u>	<u>3,453,716</u>

Management fees

The following annual management fee applies per Unit Class:

- AESCAP Life Sciences Manager: 0%
- AESCAP Life Sciences Investors: 1.5%
- AESCAP Life Sciences Investors <500k: 1.5%
- AESCAP Life Sciences Investors 10M+: 1.35%
- AESCAP Life Sciences Investors 20M+: 1.2%
- AESCAP Life Sciences Investors 30M+: 1%
- AESCAP Life Sciences Investors N: 1.5%

The mentioned fees are calculated on a bi-monthly basis based on the Net Asset Value of the Fund, to be paid monthly in arrears.

The minimum management fee will at all times be at least EUR 75,000 per annum (net of any VAT). In case the management fee falls below this level the Fund will be liquidated.

Performance fees

The following performance fee applies per Unit Class:

- AESCAP Life Sciences Manager: 0%
- AESCAP Life Sciences Investors: 20%
- AESCAP Life Sciences Investors <500k: 20%
- AESCAP Life Sciences Investors 10M+: 18%
- AESCAP Life Sciences Investors 20M+: 16%
- AESCAP Life Sciences Investors 30M+: 15%
- AESCAP Life Sciences Investors N: 20%

A performance fee which will be calculated twice a month and paid on a monthly basis and is calculated as follows:

(i) the increase in the Net Asset Value per Series (Net Asset Value per Series before performance fee) during the particular time period commencing as of the moment of subscription.

minus:

(ii) the total number of outstanding Units in that Series at the end of the month.

The calculated performance fee will not be due, in case the Net Asset Value per Series on the date on which the calculation is made is lower than the "High Watermark" (the highest Net Asset Value per Series in the preceding existence of the Fund). Accordingly, performance fees (and reservations made in respect thereof) may differ depending on the moment an investor has invested in the Fund. In order to prevent these inequities, different Series are issued. Specific Series may be converted into other Series if the inequities for performance fee in relation to the historic high watermark calculation have been balanced out. A reservation for the performance fee is made in the calculation of the Net Asset Value of the respective Series. Performance fees may differ depending on the moment an investor redeems from the Fund. A redemption from an investor may trigger a performance fee payment in case the Net Asset Value at redemption exceeds the High Watermark.

Aescap Life Sciences

Notes to the Profit & Loss Account

11.2 Other expenses

	01-01-21 / 30-06-21	01-01-20 / 30-06-20
Administration Fee	61,006	53,136
Audit Fee *	8,970	8,995
Custodian, Depository and Legal Owner Fee	31,457	26,720
Other	19,271	21,525
	<u>120,704</u>	<u>110,376</u>

* The audit fees fully relate to the audit of the financial statements of the fund. The auditor provides no other services.

Ongoing Cost Figure (OCF)

The OCF is calculated by dividing the total expenses (performance fee excluded) by the Average Net Asset Value. The Average Net Asset Value is based on the number and frequency of NAV Calculation. The Average Net Asset Value for the reporting period for Aescap Life Sciences Investors Unit Class (Lead Series) equal to € 138,180,675 and the management fee for this Unit Class during the reporting period equal to € 1,038,305 resulting in 0.75% (1.50% annually) for management fees for Aescap Life Sciences Investors Unit Class (Lead Series). The Total other expenses for the reporting period for Aescap Life Sciences Investors Unit Class (Lead Series) equal to € 86,620 resulting in 0.06% (0.12% annually) for other expenses based on an average Net Asset Value of € 138,80,675. This results in a total OCF figure of 0.81% (1.62% annually) for the reporting period for Aescap Life Sciences Investors Unit Class (Lead Series).

For the reporting period the OCF of the fund is equal to: 0.81% (annually 1.62%).

For the reporting period the OCF (including performance fee) of the fund is equal to: 0.83% (annually 1.66%).

In the prospectus the OCF of the fund is estimated to be 1.606% per annum, assuming an average Net Asset Value of the fund of € 150 million (1.598% for a Net Asset Value of the fund of € 250 million) . The OCF figures as disclosed above are valid for the Aescap Life Sciences Investors Unit Class whereas the fund management shares do not have management fees and performance fees included.

Portfolio Turnover Ratio (PTR)

The portfolio turnover ratio is calculated as follows: the total sum of purchases plus sales minus subscriptions minus redemptions divided by the average Net Asset Value. The average Net Asset Value of the Fund for the reporting period is calculated as described in the Ongoing Cost Figure paragraph.

PTR of the fund for the reporting period equals to: 56.55%.

Contractual agreement Depository

The Fund has entered into a depository agreement with Darwin Depository Services B.V.. For the Depository Services the Depository charges an annual amount equal to:

1. 0.014% of the Net Asset Value of the Fund for the Fund having a Net Asset Value of up to EUR 250 million and;
2. 0.012% of the Net Asset Value of the Fund for the Fund having a Net Asset Value between EUR 250 million and EUR 350 million and;
3. 0.01% of the Net Asset Value of the Fund for the Fund having a Net Asset Value above EUR 350 million.

When exceeding a layer threshold, the calculated amount can never be less than the total amount calculated in the previous layer. The minimum annual fee is EUR 16,500 (excluding VAT), payable quarterly in advance.

Aescap Life Sciences

Comparison of Real Cost with Cost According to Prospectus Aescap Life Sciences Investors Unit Class (Lead Series) *

	According to prospectus *	Actual costs	Actual %
Management Fee (excl. VAT)	1.500%	1,038,305	0.751%
Incentive Fee (excl. VAT)	PM	28,088	PM
Legal Owner Manager Fee (incl. VAT)	0.008%	4,398	0.003%
Administrators Fee (excl. VAT)	0.060%	41,359	0.030%
Depository Fee (excl. VAT)	0.014%	11,726	0.008%
Audit costs (incl. VAT)	0.012%	6,104	0.004%
Miscellaneous costs – incl. write off formation expenses – (incl. VAT)	0.011%	23,033	0.017%
	<u>1.605%</u>	<u>1,153,013</u>	<u>0.814%</u>

* As tabled in the Prospectus, OCF will be around 1.605% on an annual basis at a fund size of € 150 million. This projected OCF number is valid for the Aescap Life Sciences Investor Unit Class (Lead Series). For the reporting period the actual OCF for the Aescap Life Sciences Investors Unit Class (Lead Series) was more or less in line with this projected percentage.

12. Related party transactions

Related party transactions are transfers of resources, services or obligations between related parties and the Fund, regardless of whether a price has been charged. Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions or is part of key management of the Fund. The following provides details on the related parties of the Fund and transactions with the related parties.

The Fund Manager is considered a related party. Privium Fund Management B.V. is the Fund Manager of the Aescap Life Sciences Fund.

Privium Fund Management B.V. was entitled for the following compensation in relation to the reporting period:

Management fee : € 1,263,471

Performance fee : € 701,203

Subscription / Redemption fees : € 19,200

13. Employees

The Fund has no employees.

Amsterdam, 30 July 2021

Fund Manager

Privium Fund Management B.V.

Aescap Life Sciences

Other Information

Distribution Policy

The dividends and interest received by the Fund, as well as possible capital gains, will not be distributed but will be re-invested, unless distribution would be deemed appropriate by the Fund Manager in connection with the regulatory status of the Fund Manager.

Fund Managers interests in the fund

As at June 30, 2021, the number of Fund Manager related Units (Aescap Life Sciences Manager) included 11,342.5267 Units. As at December 31, 2020, the number of Fund Manager related Units (Aescap Life Sciences Manager) included 11,277.4464 Units.

The Portfolio Manager of the Fund, Patrick Krol, holds the following positions through his management company (Inspirational Visions B.V.) as per June 30, 2021 respectively December 31, 2020 in investments in company's in which the Fund has been invested:

Name	Currency	30-06-21 Number of shares	31-12-20 Number of shares
ProQR Therapeutics	USD	56,713	56,713
Excicure	USD	-	47,680
uniQure NV	USD	1,350	1,350
Galapagos	EUR	5,240	3,290
Dicerna Pharmaceutical	USD	-	2,500
Ionis Pharmaceuticals	USD	1,100	-

Independent Auditor's report

This semi annual report has not been reviewed by the independent auditor.